Expression of ERCC5(XPG)in Relation to Platinum-based Resistance in Non-small Cell Lung Cancer
|Keywords||Non - small cell lung cancer ERCC5 Platinum-Resistant Individualized chemotherapy Immunohistochemistry RT-PCR|
The purpose of application of immunohistochemistry and RT-PCR method to detect non-small cell lung cancer (non-small cell lung cancer, NSCLC) organization with paraneoplastic organizations in ERCC5 protein and mRNA expression levels of genes ERCC5 explore ERCC5 proteins differentially expressed in NSCLC pathological features and applications containing platinum chemotherapy survival the period between ERCC5 become individualized chemotherapy of NSCLC platinum potential predictors provide theoretical and experimental evidence. 1 immunohistochemical two-step detection February 2002 February 2006 Liaoning Medical College Hospital thoracic surgery treatment of 86 patients with NSCLC the postoperative lung tissue in patients with cancer and adjacent tissue specimens ERCC5 protein expression levels, investigate the expression of different types of pathology in NSCLC clinical characteristics in NSCLC development role. 2, by reverse transcription polymerase chain reaction (RT-PCR) technology to detect thoracic surgery treatment Liaoning Medical College Hospital in February 2010 -2010 in December postoperative lung tissue from 30 patients with NSCLC and paraneoplastic tissue ERCC5 mRNA expression level, to understand the relationship between the protein expression and mRNA expression. 3 through 86 cases of NSCLC patients after clinical follow-up study to examine the protein expression levels of ERCC5 with platinum-based chemotherapy, survival (1 -, 3 - and 5-year survival rate and median overall survival, with a median time to disease progression The relationship between the median survival period). Results 1 ERCC5 protein in NSCLC tissues positive expression rate was 46.51%, in adjacent tissues positive expression rate of 22.09%, the difference was statistically significant (P lt; 0.05). 2, ERCC5 protein expression levels and the degree of differentiation of NSCLC, the worse the degree of differentiation of the lower, ERCC5 positive rate, well-differentiated in differentiation the group ERCC5 expression compared with poorly differentiated undifferentiated group, the difference was significant (P lt; 0.05). And the patient's gender, age, pathological type, lymph node metastasis, regardless of the difference was not statistically significant (P> 0.05). 3, ERCC5 gene mRNA in NSCLC tissues positive expression rate of 50.00% in the cancer tissue positive expression rate of 23.33%, respectively, the difference was significant (P lt; 0.05). 4,86 NSCLC patients, surgery alone group (36 cases): which ERCC5 protein positive expression group with negative expression after 1 -, 3 -, and 5-year survival rate was significantly improved median OS, median TTP MST, compared with negative expression group was significantly longer, the difference was significant (P lt; 0.05). 5,86 NSCLC patients, postoperative chemotherapy (n = 50): which ERCC5 proteins positive expression group with negative expression group compared with the 1 -, 3 - and 5-year survival rate after surgery was no significant improvement, and the median OS, median no significant extension of TTP, MST, compared with negative expression group, the difference was not statistically significant (P> 0.05). Conclusion the ERCC5 protein expression levels with tumor invasiveness and malignant behavior related, ERCC5 protein decreased, suggesting that, ERCC5 protein may become NSCLC level of malignancy ERCC5 development plays an important role in the occurrence of malignant tumors, with the lower the degree of differentiation of NSCLC prognostic factor. , ERCC5 the mRNA differential expression in NSCLC tissues may be one of the main mechanisms of protein differentially expressed. 3, ERCC5 may be associated with NSCLC platinum-based chemotherapy resistance, ERCC5 may become NSCLC platinum-based chemotherapy sensitive predictors, and guide individualized chemotherapy.